Identification of physiologic treatment targets with favourable haemodynamic consequences in heart failure with preserved ejection fraction

David M. Kaye¹,²,³*, Melissa Byrne², Justin Marian¹,²,³, Shane Nanayakkara¹,²,³ and Daniel Burkhoff⁴

¹Department of Cardiology, Alfred Hospital, Melbourne, VIC, Australia; ²Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia; ³Department of Medicine, Monash University, Melbourne, VIC, Australia; ⁴Columbia University Medical School, New York, NY, USA

Abstract

Aims Heart failure with preserved ejection fraction (HFpEF) is characterized by complex pathophysiology including an impaired diastolic reserve. We recently showed that milrinone favourably modifies filling pressures at rest and during exertion in HFpEF patients; however, the responsible mechanism is uncertain. The objective of this study was to develop a clearer understanding of the acutely modifiable physiologic parameters that may be targeted in HFpEF.

Methods and results We conducted computer modelling simulations based on invasive haemodynamic assessments, by right heart catheterization, in HFpEF patients at baseline and in response to milrinone. Our aim was to develop a detailed understanding of the physiologic mechanisms, which accounted for the observed actions. The resultant circulatory model of HFpEF encompassed the left ventricular (LV) end-systolic and end-diastolic pressure–volume relations, together with stressed blood volume, heart rate, and arterial mechanics. To support the modelled action of milrinone, we conducted complementary LV conductance catheter and echocardiography studies in sheep to evaluate LV end-systolic and end-diastolic pressure–volume relations. In HFpEF patients, the acute haemodynamic effects of intravenous milrinone (n = 10) administration compared with placebo (n = 10) included significant reductions in right atrial pressure (7 ± 1 to 3 ± 1 mmHg, P < 0.001) and pulmonary capillary wedge pressure (13 ± 1 to 8 ± 1 mmHg, P < 0.001), while cardiac index increased (2.77 ± 0.19 to 3.15 ± 0.14 L/min/m², P < 0.05), and mean arterial pressure remained unchanged (95 ± 2 to 93 ± 3 mmHg, P = not significant). Computer simulations showed that these haemodynamic effects were explained by a concomitant 31% reduction in stressed blood volume together with 44% increase in LV end-systolic elastance (LV E₉₀). Individual changes in these parameters were not sufficient to explain the haemodynamic effects of milrinone. In vivo studies conducted in sheep (n = 5) showed that milrinone reduced LV filling pressure (8.0 ± 0.8 to 2.7 ± 0.6 mmHg, P < 0.01) and increased LV E₉₀ (0.96 ± 0.07 to 2.07 ± 0.49, P < 0.05), while no significant effect on LV stiffness was observed (0.038 ± 0.003 to 0.034 ± 0.008, P = not significant).

Conclusions These data demonstrate that stressed blood volume in HFpEF represents a relevant physiologic target in HFpEF; however, concomitant modulation of other cardiovascular parameters including LV contractility may be required to achieve desirable haemodynamic effects.

Keywords Heart failure with preserved ejection fraction; Haemodynamics; Circulatory modelling

Introduction

Heart failure with preserved ejection fraction (HFpEF) has emerged as one of the commonest and most challenging problems in contemporary cardiovascular medicine. As yet no specific therapy has been demonstrated to consistently improve all of the key treatment objectives, including quality of life, heart failure (HF) hospitalization, or survival.¹ To a certain extent, the challenges presented in identifying effective HFpEF therapies lie in the heterogeneous pathophysiological
nature of the disorder and in the frequent concurrence of co-morbidities that complicate therapy and the likelihood of benefit. Additionally, the complexities of accurate diagnosis in HFrEF using non-invasive means for the purposes of trial inclusion are recognized.

For HFrEF patients, exertional dyspnoea and corresponding exercise intolerance are cornerstone symptoms. Increased left atrial (LA) pressure, particularly during exertion, has been implicated as a principal determinant of functional capacity and potentially outcome.\(^5\) Accordingly, impaired left ventricular (LV) diastolic performance and its respective components have received particular attention as a key determinant of LA pressure. Recently, the pathophysiologic derangements that underpin HFrEF have been appreciated as being more complex and are likely to include contributions from reduced contractility, increased LA stiffness, volume overload, and dynamic mitral regurgitation,\(^5\) all of which influence LA pressure.

Previously, we investigated the effects of milrinone, a phosphodiesterase type III inhibitor, on exercise haemodynamics in HFrEF patients.\(^7\) Our study demonstrated favourable effects on pulmonary capillary wedge pressure (PCWP) at rest and during exertion; however, we did not determine the precise physiological basis for this observation. The beneficial haemodynamic actions of phosphodiesterase type III inhibition could be explained by physiologic actions including pulmonary and systemic vasodilation (of both arterial and venous beds), positive lusitropy, and positive inotropy. A clearer understanding of the mechanism could inform the development of more effective treatments. Thus, the objective of the current study was to explore the physiological basis for the haemodynamic effects of milrinone in HFrEF using complementary clinical and experimental approaches. To obtain a comprehensive evaluation, complementary computer modelling and animal experimental studies were performed in patients with HFrEF and in an animal model. Computer models were derived using clinical data applied to a previously developed and validated cardiovascular simulation\(^8\) that was used to define the relative contributions of changes in contractility, diastolic properties, heart rate, and vascular tone.

### Methods

#### Clinical study

Patients referred for haemodynamic evaluation of patients with known HFrEF or suspected HFrEF were recruited into the study \((n = 20)\). HFrEF patients were included on the basis of the presence of signs and/or symptoms consistent with a diagnosis of HF (New York Heart Association II–III), an LV ejection fraction > 50%, and a haemodynamic profile that included PCWP ≥ 15 mmHg at rest or ≥ 25 mmHg during symptom limited exercise.\(^9,10\) In the HFrEF cohort, patients were excluded in the presence of diagnoses including known coronary disease requiring revascularization, infiltrative cardiomyopathy, constrictive pericarditis, and moderate or greater valvular heart disease. Aspects of this study have been previously published in brief form, with a focus on the influence of milrinone on exercise haemodynamics.\(^7\) The study was approved by the Alfred Hospital Research and Ethics Committee, and all participants provided written informed consent.

#### Cardiac catheterization protocol

Arterial and central haemodynamics were measured as previously described.\(^2\) In brief, patients were evaluated in the non-fasted, medicated state. Haemodynamic evaluation was conducted using a 7 Fr thermodilution catheter advanced via a brachial or right internal jugular sheath. Right atrial (RA), right ventricular (RV), pulmonary arterial (PA), and pulmonary capillary wedge pressures were measured at end expiration. Following assessment of baseline haemodynamics, diagnostic supine cycle ergometry was conducted to confirm the presence of HFrEF. Subjects were randomized according to a computer-generated random order, with study drug allocation assigned using sealed envelopes opened following confirmation of HFrEF. Patients received either milrinone (50 μg/kg over 10 min) or an equivalent volume of saline (\(n = 10\) per group). All investigators except for the study nurse were blinded to group allocation. Haemodynamic evaluation was performed 10 min after the conclusion of the infusion. Pulmonary and systemic arterial compliances (PAC and SAC) were calculated as the ratio of thermodilution-derived stroke volume to the pulmonary and systemic arterial pulse pressure, respectively. Systemic arterial elastance (\(E_s\)) was calculated as \(0.9 \times \) systemic systolic blood pressure/stroke volume, and pulmonary arterial elastance (\(E_{pa}\)) was calculated as the PA systolic pressure divided by stroke volume.

#### Mathematical modelling of clinical data

In order to investigate the physiological basis of the haemodynamic effects of milrinone observed in HFrEF patients, we employed a comprehensive cardiovascular simulation, ‘Harvi’,\(^11\) which has been described in detail previously\(^8\) and which has been used to understand and explain various aspects of HF physiology.\(^12\) In brief, this models the entire circulatory system as a series of resistance and capacitive elements, with heart chambers modelled as time-varying elastics and valves modelled as diodes. The time-varying elastance model allows for characterization of systolic and diastolic chamber properties. Details of this model are provided in detail in the Appendix. This simulation has a ‘patient fitting algorithm’, which employs a custom-designed parameter search routine that simultaneously adjusts multiple model parameter values to reproduce the desired haemodynamic state including heart rate, cardiac output, ventricular sizes,
and central and systemic arterial and venous blood pressures. As detailed in the Appendix, RV and LV contractilities [indexed by end-systolic elastances (Ees)] and diastolic stiffnesses [indexed by an α constant], SAC and PAC, and stressed blood volume (described in the next paragraph) are among the key parameters that are adjusted to achieve the fit. Total systemic and pulmonary vascular resistances (SVR and PVR) were set according to measured values, but the distribution of resistances across the circulation was allowed to vary to recreate pulse pressures. Heart rate was also set to directly measured values. Resultant haemodynamic signals (pressure–volume loops and time-domain pressure and volume signals) are provided by the simulation and can be used to infer pathophysiologic status or effect of devices and drugs.13

As noted previously, stressed blood volume is a key parameter that is varied to optimize the simulation fit of real data. Despite the fact that the concepts of stressed and unstressed blood volumes are fundamental to understanding regulation of cardiovascular performance,12,14 they are not widely appreciated within the clinical community. Generally speaking, unstressed blood volume is the amount of blood required to fill the dead space in the vascular system, above which vascular wall tension and intravascular pressures start to rise. The analogy can be made to an unfilled balloon; a certain amount of air is required to just start generating positive wall stress and balloon pressure. Stressed blood volume is simply the volume above the stressed blood volume that actually contributes to generating active pressure within the vessels. Very importantly, the partitioning of blood between stressed and unstressed compartments is functional, not anatomical in nature. Every vascular structure and cardiac chamber has its own unstressed volume; the unstressed volume of the entire circulation is the sum of unstressed volumes of all vascular structures included in the circulation. Total blood volume is the sum of stressed and unstressed blood volumes. However, with changes in vascular tone (e.g. by changes in autonomic tone or administration of vasoactive drugs), there can be a redistribution of blood between functional compartments. Thus, despite constant blood volume, change in stressed blood volume has the potential to exert powerful control of cardiovascular performance.

Animal procedures

Studies performed in animals were approved by the Animal Ethics Research Committee, Victorian Institute of Animal Science (VIAS), and the animals were handled in accord with the National Institutes of Health guidelines on the Care and Use of Laboratory Animals. Five adult cross-bred sheep were included in the study. Evaluation of cardiac function was performed under individually titrated anaesthesia (comprising isoflurane and propofol) using echocardiography and LV conductance catheterization, as previously performed by us.15

Echocardiography, haemodynamics, and conductance catheterization

Echocardiographic images were obtained from short-axis and long-axis views to obtain 2D measurements of the left ventricle to estimate LV volumes. A 7 Fr pressure–volume catheter (Model CA-71103-PN; CD Leycom, the Netherlands) was advanced into the LV cavity under fluoroscopic guidance via an 8 Fr right carotid arterial sheath. In conjunction, a 14 Fr Fogarty catheter (Model 62080814F; Edwards Lifesciences, Irvine, CA, USA) was positioned in the inferior vena cava via the right internal jugular vein. Pressure–volume loops were recorded under stable haemodynamic conditions and then obtained during inferior vena cava balloon occlusion to derive the end-systolic and end-diastolic pressure–volume relationships (ESPVR and EDPVR). Following baseline measurement, milrinone (50 μg/kg) was infused over 10 min, and assessment of LV pressure–volume relationships was again obtained. Offline analysis of obtained data was performed using Conduct NT software (version 2.8.1; CD Leycom) with volume calibration performed using echocardiographic estimates of LV volumes. The ESPVR was identified to derive the Ees. Evaluation of diastolic performance was conducted by assessing the time constant of isovolumetric relaxation (τ) and the minimal rate of LV pressure change (dP/dtmin) and by determining LV stiffness from the EDPVR noted previously. Given the curvilinear nature of the EDPVR, we derived an index of LV stiffness from the relationship: α = (loge 2.33 × Psys)/Ves, based on Mirsky and Parmley.16

Statistical analysis

Data are presented as mean ± standard error of the mean. Within-subject comparisons were performed using a paired Student’s t-test or Wilcoxon test as appropriate. A P value of <0.05 was considered to be statistically significant. Statistical analysis was performed using IBM SPSS Statistics version 25 (IBM, Armonk, NY).

Results

The study comprised 20 patients (12 female and 8 male), aged 68 ± 2 years, with an LV ejection fraction 64% ± 2% and body mass index 31 ± 1 kg/m². Background medications included angiotensin-converting enzyme/angiotensin receptor blockers (85%), beta-blockers (30%), spironolactone (15%), and calcium channel blockers (40%). There were no significant differences between patients randomized to milrinone or vehicle. N terminal pro brain natriuretic peptide levels and echocardiography were not obtained at the time of the study.
Baseline haemodynamics and response to intravenous milrinone in heart failure with preserved ejection fraction

As shown in Table 1, HFpEF patients subsequently randomized to either vehicle or milrinone were well matched at baseline. In response to milrinone, there were statistically significant reductions in the PCWP (13 ± 1 to 8 ± 1 mmHg, \( P < 0.001 \)), RA pressure (7 ± 1 to 3 ± 1 mmHg, \( P < 0.001 \)), SVR (16.6 ± 1.3 to 14.8 ± 1.1 mmHg/L/min, \( P < 0.05 \)), and pulmonary artery mean pressure (23 ± 2 to 19 ± 3 mmHg, \( P < 0.01 \)), while there were modest increases in heart rate (70 ± 3 to 77 ± 4 b.p.m., \( P < 0.01 \)) and cardiac index (2.77 ± 0.19 to 3.15 ± 0.14 L/min/m², \( P < 0.05 \)) as detailed in Table 2. There were no significant changes in LV or RV stroke work index. Milrinone was also without any effect on PVR or PAC and SAC and elastances.

Modelling the circulatory effects of milrinone

To investigate the physiological basis for the effects of milrinone in individuals with HFpEF, we modelled the group average resting and post-milrinone haemodynamics in the cardiovascular simulator. Measured parameters, including heart rate, SVR, and PVR, were set according to measured values. Values of other key model parameters were adjusted to optimize the concordance between measured and simulated cardiovascular variables. As detailed in Table 3, the simulation recreated the average patient data with high degree of accuracy, precisely recreating cardiac output and simulating pressures within 1–2 mmHg for all measurements. Under baseline conditions, key parameters characterizing ventricular properties included an LV \( E_{\text{es}} \) of 2.09 mmHg/mL, an LV stiffness constant, \( \alpha \), of 0.030 mL⁻¹, an RV \( E_{\text{es}} \) of 0.35 mmHg/mL, an RV stiffness of 0.022 mL⁻¹, and a stressed blood volume of 1539 mL. Additional details of model parameter values are provided in Table A1. The resultant baseline LV pressure–volume loops with constraining ESPVR and EDPVR are presented in Figure 1.

The same process was repeated for haemodynamics during milrinone infusion, with resulting parameters and pressure–volume loops also shown in Table 3 and Figure IA, respectively. As for the baseline state, the simulation reproduced cardiac output and all pressures with a high degree of accuracy. As measured clinically, there was no significant change in PVR, but SVR decreased from 15.95 to 14.42 Wood units (mmHg·min/L). As shown, the simulation suggests that there were increases of contractility with LV and RV \( E_{\text{es}} \) values increasing to 3.00 and 0.46 mmHg/mL, respectively. However, there were no significant changes in LV or RV stiffness, but there was a significant reduction of stressed blood volume to 1066 mL. The predicted LV pressure–volume loop during milrinone infusion is also shown in Figure 1.

To investigate the relative contribution of each parameter affected by milrinone, we introduced the changes of parameter values obtained by fitting the haemodynamics during milrinone exposure on an individual basis (Figure 1B–E and Table 4). Compared with the baseline state, the observed increase in the heart rate from 70 to 77 b.p.m. and the reduction in SVR from 15.95 to 14.42 mmHg/L/min exerted very little influence on the LV pressure–volume loop or haemodynamic parameters (Figure 1B,C). Increases in ventricular contractility resulted in increases in blood pressure and cardiac output beyond those observed in the clinical setting, and there was no reduction of filling pressures (Figure 1D). In contrast, the reduction of stressed blood volume from 1539 to

Table 1  Baseline haemodynamic parameters

| Parameter                              | Vehicle (n = 10) | Milrinone (n = 10) | P value |
|----------------------------------------|-----------------|-------------------|---------|
| Heart rate (b.p.m.)                    | 67 ± 5          | 70 ± 3            | 0.55    |
| Systolic blood pressure (mmHg)         | 155 ± 7         | 149 ± 4           | 0.47    |
| Mean arterial pressure (mmHg)          | 101 ± 4         | 95 ± 2            | 0.11    |
| Right atrial pressure (mmHg)           | 6 ± 1           | 7 ± 1             | 0.43    |
| PA systolic pressure (mmHg)            | 31 ± 3          | 36 ± 4            | 0.30    |
| PA mean pressure (mmHg)                | 20 ± 2          | 23 ± 2            | 0.25    |
| PCWP (mmHg)                            | 11 ± 1          | 13 ± 1            | 0.33    |
| Cardiac index (L/min/m²)               | 2.7 ± 0.2       | 2.8 ± 0.2         | 0.74    |
| Derived cardiac indices                |                 |                   |         |
| LVSWI (g/m²/beat)                      | 8.0 ± 4.8       | 73.3 ± 5.4        | 0.36    |
| RVSWI (g/m²/beat)                      | 8.1 ± 0.9       | 8.7 ± 0.9         | 0.65    |
| Derived vascular indices               |                 |                   |         |
| SVR (mmHg/L/min)                       | 20.1 ± 1.7      | 16.6 ± 1.3        | 0.11    |
| PVR (mmHg/L/min)                       | 1.8 ± 0.2       | 1.9 ± 0.3         | 0.78    |
| SA compliance (mL/mmHg)                | 1.02 ± 0.12     | 1.00 ± 0.09       | 0.96    |
| PA compliance (mL/mmHg)                | 4.19 ± 0.38     | 4.19 ± 0.53       | 1.0     |
| SA elastance (mmHg/mL)                 | 1.90 ± 0.16     | 1.75 ± 0.11       | 0.43    |
| PA elastance (mmHg/mL)                 | 0.40 ± 0.03     | 0.47 ± 0.06       | 0.34    |

LVSWI, left ventricular stroke work index; PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RVSWI, right ventricular stroke work index; SA, systemic arterial; SVR, systemic vascular resistance.

ESC Heart Failure 2020; 7: 3685–3693
DOI: 10.1002/ehf2.12908
1036 mL caused marked reductions of mean RA pressure and PCWP, in line with those observed in patients, albeit at the cost of systemic hypotension (Figure 1E).

Effects of milrinone on left ventricular performance in experimental animals

To complement the simulation studies, we examined the effect of milrinone on LV performance in sheep by conductance catheterization. As demonstrated in Table 5, similar effects to those seen in HFpEF patients were observed. Specifically, there was a significant reduction in LV end-diastolic pressure with preservation of the systolic pressure. Acute infusion of milrinone was associated with an increase in LV Ees. A detailed examination of the effects of milrinone on diastolic performance showed no effect on the time constant of relaxation, r. As shown in Figure 2, infusion of milrinone was associated with a downward and leftward shift of the diastolic portion of the pressure–volume loop but along a

Table 2 Effects of milrinone on resting haemodynamics

| Placebo (n = 10) | Milrinone (n = 10) | P value |
|------------------|------------------|--------|
| Heart rate (b.p.m.) | −0.4 ± 1.2 | 6.9 ± 1.5 | 0.001 |
| Systolic blood pressure (mmHg) | 0.6 ± 3.6 | 3.5 ± 3.2 | 0.55 |
| Mean arterial pressure (mmHg) | −0.5 ± 2.3 | −1.6 ± 1.6 | 0.70 |
| Right atrial pressure (mmHg) | −0.3 ± 0.4 | −3.2 ± 0.6 | 0.001 |
| PA systolic pressure (mmHg) | −0.5 ± 1.1 | −4.4 ± 1.8 | 0.09 |
| PA mean pressure (mmHg) | −1.0 ± 1.0 | −4.3 ± 1.3 | 0.04 |
| PCWP (mmHg) | 0.1 ± 0.5 | −5.6 ± 1.1 | <0.001 |
| Cardiac index (L/min/m²) | −0.1 ± 0.1 | 0.4 ± 0.1 | 0.004 |
| Derived cardiac indices |  |  |  |
| LVSWI (g/m²/beat) | −1.2 ± 2.4 | 7.4 ± 4.7 | 0.12 |
| RVSWI (g/m²/beat) | −0.8 ± 0.5 | 0.1 ± 1.1 | 0.46 |
| Derived vascular indices |  |  |  |
| SVR (mmHg/L/min) | −1.8 ± 0.8 | 1.0 ± 0.8 | 0.02 |
| PVR (mmHg/L/min) | −0.2 ± 0.2 | 0.0 ± 0.2 | 0.67 |
| SA compliance (mL/mmHg) | −0.10 ± 0.07 | −0.06 ± 0.05 | 0.60 |
| PA compliance (mL/mmHg) | 0.68 ± 0.66 | 0.36 ± 0.35 | 0.67 |
| SA elastance (mmHg/mL) | 0.07 ± 0.06 | −0.03 ± 0.08 | 0.32 |
| PA elastance (mmHg/mL) | 0.02 ± 0.03 | −0.08 ± 0.03 | 0.02 |

LVSWI, left ventricular stroke work index; PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RVSWI, right ventricular stroke work index; SA, systemic arterial; SVR, systemic vascular resistance.

Table 3 Simulation input and output parameters

| Haemodynamic parameter | Baseline | Milrinone |
|------------------------|----------|-----------|
| Observed | Computer simulation | Observed | Computer simulation |
| Arterial BP (mmHg) | 149/68 (95) | 149/65 (94) | 153/64 (94) | 153/63 (92) |
| Heart rate (b.p.m.) | 70 | 70 | 77 | 77 |
| Cardiac output (L/min) | 5.6 | 5.6 | 6.3 | 6.3 |
| RA pressure (mmHg) | 7 | 8 | 3 | 4 |
| PA pressure (mmHg) | 36/14 (23) | 37/15 | 32/11 (19) | 31/11 (17) |
| PCWP (mmHg) | 14 | 14 | 8 | 8 |
| Model parameter |  |  |  |  |
| LV Ees (mmHg/mL) | 2.09 | 3.00 |
| LV stiffness (mL⁻¹) | 0.030 | 0.028 |
| LVEDV (mL) | 135 | 116 |
| LVEDP (mmHg) | 18 | 9 |
| LVESV (mL) | 60 | 38 |
| LVESP (mmHg) | 126 | 114 |
| RV Ees (mmHg/mL) | 0.35 | 0.46 |
| RV stiffness | 0.022 | 0.018 |
| SVR (mmHg·min/L) | 15.95 | 14.42 |
| PVR (mmHg·min/L) | 1.66 | 1.69 |
| Stressed blood volume (mL) | 1539 | 1066 |

BP, blood pressure; LV, left ventricle; LV Ees, left ventricular end-systolic elastance; LVEDP, left ventricular end-diastolic pressure; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular systolic volume; PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RA, right atrial; RV, right ventricle; RV Ees, right ventricular end-systolic elastance; SVR, systemic vascular resistance.

ESC Heart Failure 2020; 7: 3685–3693
DOI: 10.1002/ehf2.12908
common EDPVR assessed during preload manipulation by balloon occlusion of the inferior vena cava. In this analysis, milrinone caused a small, non-significant reduction in LV stiffness from \(0.038 \pm 0.003\) to \(0.034 \pm 0.008\) (Table 5).

Discussion

Elevated LA pressure is a hallmark feature of HFrEF, particularly in the context of physical activity. The extent of the rise has been associated with both functional capacity and outcomes. We previously showed that milrinone administered intravenously was able to reduce the PCWP in HFrEF patients especially during exercise. In the current study, we sought to investigate physiologic mechanisms underlying this observation using both computer-based simulations and experimental in vivo studies. The results suggest that the actions of milrinone were predominantly explained by a concomitant reduction in stressed blood volume together with an enhancement of LV contractility.

Given the central role of LA pressure elevation in the pathogenesis of HFrEF, advancement of the field and the development of effective HFrEF therapy requires a comprehensive consideration of the contributing mechanisms. LA pressure is determined by a complex interaction of factors...
Table 5  Effects of milrinone on left ventricular mechanics in sheep

|                      | Baseline        | Milrinone     | P value |
|----------------------|-----------------|---------------|---------|
| LVEDP (mmHg)         | 8.0 ± 0.8       | 2.7 ± 0.6     | <0.01   |
| LVESP (mmHg)         | 76 ± 2          | 65 ± 5        | 0.08    |
| LVEDV (mmHg)         | 75 ± 6          | 47 ± 3        | <0.01   |
| LVESV (mmHg)         | 29 ± 3          | 8 ± 3         | <0.01   |
| Heart rate (b.p.m.)  | 93 ± 6          | 106 ± 4       | 0.08    |
| LV dp/dtmin          | −1420 ± 109     | −1069 ± 11    | <0.05   |
| LV τ                 | 26.2 ± 1.0      | 28.6 ± 2.2    | 0.48    |
| LV Ees               | 0.96 ± 0.07     | 2.07 ± 0.49   | <0.05   |
| LV stiffness (w)     | 0.038 ± 0.003   | 0.034 ± 0.008 | ns      |

LV, left ventricular; LV Ees, left ventricular end-systolic elastance; LVEDP, left ventricular end-diastolic pressure; LVEDV, left ventricular end-diastolic volume; LVESP, left ventricular end-systolic pressure; LVESV, left ventricular end-systolic volume; ns, not significant.

In our study, at the doses used, milrinone had no effect on the rate of isovolumic relaxation in vivo. In the ovine studies, milrinone did not significantly influence LV stiffness, which was consistent with modelling estimates of HFrEF patient data. The predominant effect of milrinone in both patients and sheep was to shift the pressure–volume loops downwards and to the left along a common EDPVR; in contrast, a primary reduction in LV stiffness would be expected to shift the EDPVR downwards and rightwards. Although we did not investigate the effects of milrinone on LV stiffness directly in the clinical study, the lack of effect of milrinone on the EDPVR suggests that it may not be acutely modifiable in HFrEF patients. This point requires further investigation in clinical studies, including the measurement of detailed pressure–volume analyses. This finding may be of relevance to ongoing interest in the role of titin and its phosphorylation status in the pathophysiology of HFrEF. Protein kinase A is known to phosphorylate titin with a resultant decrease in myocardial stiffness. As a corollary, given its pharmacologic mode of action, it would be expected that milrinone would increase titin phosphorylation; however, we did not observe an alteration in LV stiffness. This finding could be explained by the overwhelming influencing of myocardial fibrosis or a lack of sensitivity of in vivo measures to detect subtle changes in myocardial stiffness per se. The clinical failure of other interventions expected to modify titin phosphorylation, such as protein kinase G activation, might also be explained by a lack of effect on LV stiffness, although this remains uncertain.

Left ventricular end-diastolic pressure is also dependent upon RV function and the central blood volume. The magnitude of a volume-mediated change in LV filling pressure is non-linear and depends on the prevailing filling status together with LV stiffness. Our modelling indicated that milrinone markedly reduced the stressed blood volume, potentially via acute splanchnic vasodilation, leading to lower filling pressures in both the right and left circulations (i.e. central venous pressure and PCWP) and potentially therefore leading to a lesser rise during physical exertion. Blood volume status in HFrEF has been reported to be expanded in patients with HFrEF when measured using radiotracer methodology, although this remains controversial when measured using other methods. Our study suggests that stressed blood volume manipulation may be a valid therapeutic strategy. However, as illustrated by our modelling data, this approach alone may contribute to hypotension. Splanchnic nerve block has also been reported as a strategy by which to modulate stressed blood volume in HF patients. BNP infusion has also been shown reductions in filling pressures, potentially due to splanchnic vasodilation. Alternately, pulmonary C-type natriuretic peptide (CNP) receptors might also play a role in haemodynamic modulation. Interestingly, a recent
mechanistic study of the effects of sacubitril/valsartan in HFrEF patients showed greater reductions in LV volumes and improved quality of life independent of a postulated change in afterload, raising the possibility of an effect on preload. From a therapeutic perspective however, it is of note that HFrEF patients with small LV cavities have been shown to have poorer exercise capacity, and in the setting of significant hypertrophy, a risk of cavity obliteration during excessive intravascular volume depletion is of concern.

Considerable evidence has accumulated to suggest that LV contractility, as measured either by strain imaging or by invasive means, is impaired at rest in some HFrEF patients and/or that there is also a failure of contractile recruitment in some HFrEF patients. Importantly, reduced global longitudinal strain has also been associated with poorer outcome in HFrEF, and we recently showed that failure of contractile recruitment is an independent contributor to the rise in LA pressure during exercise. The finding that a key mode of action of milrinone was to enhance contractility is therefore of potential benefit. Nevertheless, further studies would be required to investigate the impact of a positive inotropic intervention in HFrEF on myocardial oxygen consumption and on the potential for arrhythmic events.

The modest effects of milrinone on SVR and heart rate were also investigated in the computer simulations. Neither was associated with clinically meaningful haemodynamic changes, suggesting that the observed effects of milrinone were not primarily mediated by changes in these parameters. Similarly, we did not observe substantial acute changes in arterial elastance or pulmonary vascular mechanics, suggesting that neither of these properties was the primary mechanism involved in the acute modulation of LA or RA pressure. Consistent with these findings, nitrite has been observed to significantly decrease filling pressures, while SVR and heart rate were relatively unchanged. In the present HFrEF patient simulation, we also examined the influence of increasing the heart rate to 90 b.p.m. (data not shown), and this was also without influence on the predicted LV filling pressure. As such, it is unlikely that heart rate modification would be solely mediated by cardiac output augmentation rather than filling pressure alteration. Clinical trials of atrial pacing are ongoing in HFrEF (NCT02145351).

Taken together, the current study highlights the complex interplay between derangements in fundamental physiologic parameters that lead to the haemodynamic features commonly observed in HFrEF. By characterizing these features, we have highlighted the potential utility of interventions that target systolic performance and stressed blood volume. These hypothesis-generating conclusions may help to inform the design of future studies, which will be required to investigate whether interventions that target these factors in a durable manner provide clinical benefit.

Conflict of interest
D.M.K. is co-founder and stockholder in Cardiora, which has developed an oral formulation of milrinone for heart failure with preserved ejection fraction. Cardiora played no role in the present study. D.B. is co-founder of PV Loops LLC, which developed and distributes the Harvi cardiovascular simulation.

Funding
The study was funded with support from the National Health and Medical Research Council of Australia.

Supporting information
Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure A1
Table A1 Model parameter values

References
1. Wintrich J, Kindermann I, Ukena C, Selejan S, Werner C, Maack C, Laufs U, Tschöpe C, Anker SD, Lam CSP, Voors AA, Böhm M. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clin Res Cardiol 2020. https://doi.org/10.1007/s00392-020-01633-w
2. Maeder MT, Thompson BR, Brunner-La Rocca HP, Kaye DM. Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. J Am Coll Cardiol 2010; 56: 855–863.
3. Borlaug BA, Olson TP, Lam CSP, Flood KS, Lerman A, Johnson BD, Redfield MM. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 2010; 56: 845–854.
4. Wolks E, Kaye D, Komtebedde J, Shah SJ, Borlaug BA, Burkhoff D, Kitzman DW, Lam CSP, Van Veldhuisen DJ, Ponikowski P, Petrie MC, Hassager C, Møller JE, Gustafsson F. Central and peripheral determinants of exercise capacity in heart failure patients with preserved ejection fraction. JACC Heart Failure 2019; 7: 321–332.
5. Ho JE, Zern EK, Wooster L, Bailey CS, Cunningham T, Eisman AS, Hardin KM, Zampierollo GA, Jarolim P, Pappagianopoulos PP, Malhotra R, Nayor M, Lewis GD. Differential clinical definitions. Circulation 2019; 140: 353–365.
6. Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction.
in perspective. *Circ Res* 2019; **124**: 1598–1617.

7. Kaye DM, Nanayakkara S, Vizi D, Byrne M, Mariani JA. Effects of milrinone on rest and exercise hemodynamics in heart failure with preserved ejection fraction. *J Am Coll Cardiol* 2016; **67**: 2554–2556.

8. Doshi D, Burkhoff D. Cardiovascular simulation of heart failure pathophysiology and therapeutics. *J Card Fail* 2016; **22**: 303–311.

9. Wessler J, Kaye D, Gustafsson F, Petrie MC, Hasenfuß G, Lam CSP, Borlaug BA, Komtebedde J, Feldman T, Shah S, Burkhoff D. Impact of baseline hemodynamics on the effects of a transcutaneous interstitial shunt device in heart failure with preserved ejection fraction. *Circ Heart Fail* 2018; **11**: e004540.

10. Reddy YNV, Carter RE, Obokata M, Antfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. *Circulation* 2018; **138**: 861–870.

11. Burkhoff D, Dickstein M, Schleicher T, Harvi—online. www.harvi@pvloons.com

12. Burkhoff D, Tyberg JV. Why does pulmonary venous pressure rise after onset of LV dysfunction: a theoretical analysis. *Am J Physiol 1993; 265*: H1819–H1828.

13. Paluja M, Schrage B, Westermann D, Basir MB, Garan AR, Burkhoff D. Hemodynamic effects of mechanical circulatory support devices in ventricular septal defect. *Circ Heart Fail* 2019; **12**: e005981.

14. Gelman S. Venous function and central venous pressure: a physiologic story. *Anesthesiology* 2008; **108**: 735–745.

15. Mariani JA, Smolic A, Prevołos A, Byrne MJ, Power JM, Kaye DM. Augmentation of left ventricular mechanics by recirculation-mediated AVAV-1-SERCA2a gene delivery in experimental heart failure. *Eur J Heart Fail* 2011; **13**: 247–253.

16. Mirkar P, Parmley WM. Assessment of passive elastic stiffness for isolated heart muscle and the intact heart. *Circ Res* 1973; **33**: 233–243.

17. Dorfs S, Zeh W, Hochholzer W, Jander N, Kienzle RP, Pieke B, Neumann FJ. Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. *Eur Heart J 2014; 35*: 3103–3112.

18. Ellims AH, Shaw JA, Stub D, Iles LM, Hare JL, Slavin GS, Kaye DM, Taylor AJ. Diffuse myocardial fibrosis evaluated by post-contrast T1 mapping correlates with left ventricular stiffness. *J Am Coll Cardiol* 2014; **63**: 1112–1118.

19. Rommel KP, von Roeder M, Latuscnyski K, Oberueck C, Blazek S, Fengler K, Besler C, Sandri M, Lücke C, Guterlet M, Linke A, Schuler G, Lurz P. Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction. *J Am Coll Cardiol* 2016; **67**: 1815–1825.

20. Maurer MS, King DL, El-Khoury Rumbarger L, Packer M, Burkhoff D. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. *J Card Fail 2005; 11*: 177–187.

21. Shah AM, Claggett B, Loehr LR, Chang PP, Matsushita K, Kitzmian D, Konety S, Kuchanska-Newton A, Sueta CA, Mosley TH, Wright JD, Coresh J, Heiss G, Folsom AR, Solomon SD. Heart failure stages among older adults in the community: the Atherosclerosis Risk in Communities study. *Circulation* 2017; **135**: 224–240.

22. Linke WA, Hamdani N. Gigantic business: titin properties and function through thick and thin. *Circ Res 2014; 114*: 1052–1068.

23. Ohnuki Y, Yamada T, Mototani Y, Umecki D, Shiozawa K, Fujita T, Saeki Y, Okumura S. Effects of protein kinase A on the phosphorylation status and transverse stiffness of cardiac myofilaments. *J Pharmacol Sci 2013; 123*: 279–283.

24. Borlaug BA, Anstrom KJ, Lewis GD, Shah SJ, Levine JA, Koepp GA, Givertz MM, Felker GM, LeWinter MM, Mann DL, Margulies KB, Smith Al, Tang WHW, Whellan DJ, Chen HH, Davila-Roman VG, McNulty S, Desvigne-Nickens P, Hernandez AF, Braunwald E, Redfield MM, for the National Heart, Lung, and Blood Institute Heart Failure Clinical Research Network. Effect of inorganic nitrate vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial. *JAMA* 2018; **320**: 1764–1773.

25. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Offili EA, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. *JAMA 2013; 309*: 1268–1277.

26. Miller WL, Mullan BP. Volume overload profiles in patients with preserved and reduced ejection fraction chronic heart failure: are there differences? A pilot study. *JACC Heart failure 2016; 4*: 453–459.

27. Grodin JL, Phillips S, Mullens W, Nijst P, Martens P, Farg JC, Drazner MH, Tang WHW, Pandey A. Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT. *Eur J Heart Fail 2019; 21*: 634–642.

28. Fudim M, Jones WS, Boortz-Marx RL, Ganesh A, Green CL, Hernandez AF, Patel MR. Splanchnic nerve block for acute heart failure. *Circulation* 2018; **138**: 951–953.

29. Brunner-La Rocca HP, Woods RL, Kaye DM, Hastings J, Thomas CJ, Lambert E, Esler MD. Divergent effects of ANP and BNP in acute heart failure: evidence for a putative BNP-selective receptor? *J Hypertens 2002; 20*: 1195–1201.

30. Schwartz LA, Schwartges I, Scheeren TW, Schober P, Picker O. The differential effects of recombinant brain natriuretic peptide, nitroglycerine and dihydralazine on systemic oxygen delivery and gastric mucosal microvascular oxygenation in dogs. *Anaesthesia 2012; 67*: 501–507.

31. Egom EE, Maher V, El Hiani Y. Evolving use of natriuretic peptide receptor type-C as part of strategies for the treatment of pulmonary hypertension due to left ventricle heart failure. *Int J Cardiol 2019; 281*: 172–178.

32. Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, McCague K, Abbasi CA, Rocha R, Mitchell GF, for the EVALUATE-HF Investigators. Effect of sacubitril–valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. *JAMA 2019; 322*: 1–10.

33. Meyer M, McIntree RK, Nyotowidjojo I, Chu G, LeWinter MM. Relationship of exercise capacity and left ventricular dimensions in patients with a normal ejection fraction. *An exploratory study PLoS One 2015; 10*: e0119432.

34. Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieke B, Žiře MR, Voors AA, LeFkowitz MP, Packer M, McMurray JJV, Solomon SD. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction: *JACC 2019; 73*: 528–530.

35. Nanayakkara S, Telles F, Beale AL, Evans S, Vizi D, Marwick TH, Kaye DM. Relationship of degree of systolic dysfunction to variations in exercise capacity and hemodynamic status in HFpEF. *JACC Cardiovasc Imaging 2020; 13*: 528–530.

36. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, Pitt B, Pfeffer MA, Solomon SD. Prognostic importance of impaired systolic function in heart failure with impaired ejection fraction and the impact of spironolactone. *Circulation* 2018; **138**: 402–414.

37. Borlaug BA, Koepp KE, Melenovsky V. Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. *J Am Coll Cardiol 2015; 66*: 1672–1682.